September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Hyaluronic acid based legumain responsive nano-carrier for the targeted delivery of doxorubicin
Author Affiliations & Notes
  • Kaihui Nan
    Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
  • Tong Li
    Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
  • Peiling Xie
    Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
  • Yihong Tang
    Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
  • Sen Lin
    Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
  • Footnotes
    Commercial Relationships   Kaihui Nan, None; Tong Li, None; Peiling Xie, None; Yihong Tang, None; Sen Lin, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 767. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kaihui Nan, Tong Li, Peiling Xie, Yihong Tang, Sen Lin; Hyaluronic acid based legumain responsive nano-carrier for the targeted delivery of doxorubicin. Invest. Ophthalmol. Vis. Sci. 2016;57(12):767.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Doxorubicin (DOX) is a potent chemotherapy agent for various cancers; however, its severe side effects limit its application. Current study aimed to develop a legumain-triggered DOX release system to selectively target cancer cells, reduing off-target toxicity.

Methods : Legumain substrate peptide was synthesized using solid phase method. DOX was conjugated to the legumain using O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU) and Diisopropylethylamine (DIPEA) as the coupling agent. The conjugate (DOX-PEP-NH2) was then grafted onto hyaluronic acid (HA) in the presence of EDC/NHS to form HA-PEP-DOX. The HA-PEP-DOX was cross-linked to adipic dihydrazide in a water-in-oil emulsion to form Hyaluronic nano-spheres. The hyaluronic nano-spheres containing HA-PEP-DOX were evaluated on Y-79 cell line as well as normal ocular cell line using Cell Counting Kit (CCK-8).

Results : Successful conjugation of DOX-PEP-NH2 with the HA nanospheres was confirmed by 1H-nuclear magnetic resonance spectra (1H-NMR). High resolution transmission electron microscope (HR-TEM) revealed the nano-sphere had an average size of 365 ± 28 nm with zeta potential value of -25 mV detected using a dynamic light scattering (DLS) analyzer. The amount of DOX grafted on HA nano-spheres ranged from 0.3 µg/mg to 3.5 µg/mg depending on the feeding of DOX-PEP-NH2. The IC50 of HA-PEP-DOX nano-spheres against Y-79 cells was approximately 3 µg/mL that was significantly lower than 7.5 µg/mL for free DOX. This formulation was well tolerated on cultured retinal pigmented epithelium (RPE) cells or L929 fibroblast cells even at the concentration of 4 µg/mL (DOX equivalent).

Conclusions : HA-PEP-DOX nano-spheres can selectively inhibit cancer cell (Y-79) viability while exhibiting benign cytotoxicity on the normal cell (RPE or L929). This formulation of DOX may enhance specificity of this potent therapeutics and reduce the off-target side effects significantly when applied on ocular drug targeted delivery.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×